Compare WEAV & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | CABA |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.7M | 495.7M |
| IPO Year | 2021 | 2019 |
| Metric | WEAV | CABA |
|---|---|---|
| Price | $7.28 | $2.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $11.00 | ★ $14.50 |
| AVG Volume (30 Days) | 1.2M | ★ 3.0M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.50 | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $239,024,000.00 | N/A |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $4.24 | $1.41 |
| 52 Week High | $8.11 | $4.23 |
| Indicator | WEAV | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 53.92 |
| Support Level | $6.71 | $2.67 |
| Resistance Level | $7.35 | $3.34 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 99.06 | 72.84 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and generates revenue mainly from subscriptions.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.